Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 104, Issue 2-3, 1997, Pages 229-236

  Yamamoto, M ^a   Yokochi, M ^b   Kuno, S ^c   Hattori, Y ^d   Tsukamoto, Y ^e   Narabayashi, H ^f   Tohgi, H ^g   Mizuno, Y ^d   Kowa, H ^h   Yanagisawa, N ⁱ   Kanazawa, I ^j  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b Department of Dentistry Oral surgery   (Japan)

^c UTANO NATIONAL HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e NIPPON ROCHE RESEARCH CENTER   (Japan)

^f Neurological Clinic   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

^h KITASATO UNIVERSITY   (Japan)

ⁱ SHINSHU UNIVERSITY   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

3 O methyldopa; Catechol O methyltransferase inhibitor; Levodopa; Parkinson's disease; Tolcapone

Indexed keywords

3 O METHYLDOPA; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; TOLCAPONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030946439     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273183     Document Type: Article

References (25)

1. Barbeau A (1974) The clinical physiology of side effects in long-term L-dopa therapy. Adv Neurol 5: 347-365
2. Bartholini G, Kuruma I, Pletscher A (1971) 3-O-methyldopa, new precursor of dopamine. Nature 230: 533-534
3. Bartholini G, Kuruma I, Pletscher A (1972) The metabolic pathway of L-3-O-methyldopa. J Pharmacol Exp Ther 183: 68-73
4. Brannan T, Martínez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 42: 683-685
5. Calne DB, Reid JL, Vakil SD (1974) Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 38: 533-536
6. Cedarbaoum JM (1987) Clinical pharmacokinetics of anti-parkisonian drugs. Clin Pharmacokinet 13: 141-178
7. Dingemanse J, Jorga K, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57: 508-517
8. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987) 3-O-methyldopa and motor fluctuations in Parkinson's disease. Neurology 37: 856-859
9. Fahn S, Elton RL (1987) Members of the UPDRS development Committee, Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol II A. MacMillan Healthcare Information, Florham Park, NJ, pp 293-304
10. Gervas J, Muradas B, Bazan E, Aguado E, de Yebenes J (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278-282
11. Guttman M, Leger G, Cedarbaoum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A (1992) 3-O-methyldopa administration dose not alter fluorodopa transport into the brain. Ann Neurol 31: 638-643
12. Heinzel G, Woloszczak R, Thomann P (1993) TOPFIT version 2.0 Pharmacokinetic Data Analysis System for the PC. Gustav Fischer/VCH Publishers
13. Kaakkola S, Teräräinen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77-80
14. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253-1260
15. Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317-323
16. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet I: 345-349
17. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 186-189
18. Mouradian MM, Juncos JL, Fabbrini G, Chase TN (1987) Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22: 475-479
19. Nutt JG, Fellman JH (1984) Pharmacokinetics of L-dopa. Clin Neuropharmacol 7: 35-49
20. Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267-271
21. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1994) Catechol-O-methyltransferase inhihbitor tolcapone prolongs levodopa/ carbidopa action in parkinsonian patients. Neurology 44: 2685-2688
22. Sage JI, Mark MH (1992) The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 42 [1 Suppl I]: 23-8, discussion 57-60
23. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44: 1292-1297
24. Zürcher G, Da Prada M (1990a) Simple automated high-performance liquid chromatographic column-switched technique for the measurement of dopa and 3-O-methyldopa in plasma. J Chromatogr 530: 253-262
25. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990b) Ro40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 53: 497-503